H.C. Wainwright raises Halozyme stock price target to $95 By Investing.com

H.C. Wainwright raised Halozyme Therapeutics' price target to $95 from $90 and maintained a Buy rating, citing added RYBREVANT SC to its model and broadly aligned 2026 revenue and EBITDA expectations versus consensus. The firm is slightly below FactSet on fiscal 2026 EPS at $7.27 versus $8.06, but the overall setup remains constructive ahead of earnings in 13 days on May 12, 2026. The article also highlights a $15 million Vertex Hypercon licensing deal, ongoing SC launch momentum, and governance changes to the bylaws.

Analysis

HALO is still trading like a mature royalty compounder, but the market is likely underappreciating how incremental SC conversion and partner launch mix can re-rate the duration of its cash flows. The key second-order effect is that every successful SC transition improves not just near-term royalties, but the perception that HALO’s platform remains the default delivery layer for large biologics, which can widen the multiple even if headline growth looks only mid-teens. The market has likely already discounted stable royalty growth; what can surprise is a faster-than-modeled mix shift toward higher-quality, lower-volatility embedded royalties.

The real risk is that the stock is being priced as if EPS beats will matter more than the franchise story, while consensus already expects strong revenue scaling. If management sounds cautious on partner conversion cadence or if Keytruda litigation becomes a capital-allocation overhang, the multiple could compress before any fundamental issue shows up in reported numbers. Near term, the catalyst window is the May 12 earnings print; over the next 1-3 months, guidance on newer SC launches matters more than the quarter itself.

VRTX is a smaller but important tell: the collaboration is economically modest, yet it validates continued external demand for hyperconcentration technology. The contrarian read is that investors may be overfocusing on the direct dollar impact and underestimating how a steady stream of platform wins lowers perceived competitive risk, which is valuable for HALO’s long-duration narrative. That said, if the market starts treating these deals as “low-cheap optionality” rather than evidence of platform leadership, the stock could lag even with clean execution.

Key Decisions for Investors

• Go long HALO into earnings with a 2-4 week horizon; use common stock or at-the-money calls to capture a potential multiple expansion if management confirms SC conversion acceleration. Risk/reward favors upside because consensus already bakes in strong fundamentals, but not a narrative reset.
• Pair trade: long HALO / short a basket of lower-quality small-cap biotech platforms with weaker royalty visibility over the next 1-2 months. The trade monetizes the market’s preference for recurring cash flow and should outperform if HALO reaffirms durability.
• If you already own HALO, hedge event risk with May/June downside puts rather than selling the core position. The asymmetry is favorable: earnings disappointment or litigation headlines can hit the multiple faster than fundamentals would deteriorate.
• Avoid chasing VRTX on the collaboration headline alone; treat it as validation, not a revenue driver. If anything, use VRTX strength as a source of funds for HALO exposure, since the economic sensitivity sits with platform royalty compounding, not the headline deal size.
• Set a post-earnings trigger: add to HALO on any pullback to the low-$60s if royalty cadence and partner updates are intact. That would likely represent a better entry than pre-event buying if the market sells the print on conservative EPS guidance.